Although the remarkable antitumor efficacy of IL12 has yet to be replicated in preclinical human models, preclinical studies on the combination of IL12, IL15, and IL18 might represent ideal approaches to generating NK and DCs for cancer therapy (50, 51). The gene discussed is IL15; the disease is cancer.